Home About Us Pipeline News Investors Contacts Careers


News

Recent Press Releases Archives

Recent Press Releases

2019 News Releases

Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2019

LOS ANGELES, Calif., May 8, 2019 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 3:00 p.m. PDT on Wednesday, May 15, at the Bank of America Merrill Lynch Health Care Conference 2019. The conference will be held at Encore at the Wynn in Las Vegas.

A live webcast of the presentation will be available on the Company’s website at www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to three drug candidates — PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. NERLYNX was granted marketing authorization by the European Commission in September 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at www.pumabiotechnology.com.



Contact:
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1-424-248-6500
info@pumabiotechnology.com
ir@pumabiotechnology.com

Russo Partners
David Schull or Juliette Gorson, Russo Partners, +1-212-845-4271 / +1-212-845-4235
david.schull@russopartnersllc.com
juliette.gorson@russopartnersllc.com

# # # # #

Back to 2019 News Releases

Corporate Fact Sheet

Puma Biotechnology, Inc.

10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax